> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Prestige Consumer Healthcare Cuts Revenue Outlook To $1,280 Million-$1,290 Million As Clear Eyes Supply Stays Tight
- URL: https://www.bullished.co/prestige-consumer-healthcare-cuts-revenue-outlook-to-1-280-million-1-290-million-as-clear-52816b09/
- Published: 2026-11-05T11:28:13.000Z
- Updated: 2026-11-05T11:28:13.000Z
- Description: The company also lowered its adjusted EPS forecast to $4.48 to $4.55 on variable Clear Eyes output at its Pillar5 plant.
- Author: Matteo Parrino
- Tags: Earnings, PBH, Industry: Healthcare

Prestige Consumer Healthcare, which sells branded consumer health products including Clear Eyes, cut its fiscal 2027 revenue forecast to [$1,280 million to $1,290 million](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/exhibit991fy27-q2earningsr.htm?ref=bullished.co) from $1,290 million to $1,315 million. CEO Ron Lombardi blamed recent variability in Clear Eyes production at the company's Pillar5 plant, which he said will reduce product availability and revenue in the second half.

## Guidance comes down on every line

Adjusted diluted earnings per share are now forecast at [$4.48 to $4.55](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co), against $4.55 to $4.65 before. Organic revenue growth is now seen as about flat, versus the earlier 1% to 3%, and adjusted free cash flow at $265 million or more, from $270 million or more.

The company's slide deck says organic growth would be about 2% excluding Clear Eyes, and that it expects lower Clear Eyes sales in the second half than a year earlier. It also cites higher interest expense as a drag on EPS.

Lombardi said the outlook for the rest of the portfolio is unchanged. "While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site," he said.

## A quarter of acquisitions and a Clear Eyes decline

Second-quarter revenue [rose 22.7%](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co) to $336.3 million, helped by a $65.1 million contribution from the Breathe Right portfolio and LaCorium acquisitions. Excluding currency and acquisitions, revenue fell 1.6%, which the company tied to order timing in the first quarter and a decline in Clear Eyes.

Reported net income dropped to [$25.3 million](https://www.9news.com/article/syndication/associatedpress/prestige-consumer-healthcare-fiscal-q2-earnings-snapshot/616-97982add-3306-4774-999b-a2b1636918b5?ref=bullished.co), or $0.53 a share, from $42.2 million, or $0.86\. Adjusted EPS rose to $1.13 from $1.07\. Net interest expense climbed to $30.0 million from $10.0 million.

Adjusted gross margin was 57.7%, up from 55.3%, while the standard-accounting gross margin fell to 51.3%. Adjusted figures exclude items such as inventory step-up amortization and Pillar5 remediation costs.

## Debt now above $2 billion

Long-term debt stood at about $2.08 billion on September 30, up from $994 million at March 31, after the Breathe Right and LaCorium deals, which closed in June and July. Net debt was approximately $2 billion, and the company said paying it down is the priority for free cash flow for the rest of the fiscal year.

Prestige also issued $400 million of 6.25% senior notes due July 2034, replacing notes that had been due in fiscal 2028.

Lombardi reiterated a medium-term goal of about 10% annual revenue growth, and said the Pillar5 purchase gives the company vertical integration of its eye care supply chain.

Management hosted a call at 8:30 a.m. ET on Thursday to walk through the results and the revised outlook.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Prestige Consumer Healthcare Inc. (PBH)](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/pbh-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991fy27-q2earningsr.htm — Prestige Consumer Healthcare Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/exhibit991fy27-q2earningsr.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit992pbh\_fy27xq2.htm — Prestige Consumer Healthcare Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/exhibit992pbh%5Ffy27xq2.htm?ref=bullished.co) — SEC EDGAR
- [Prestige Consumer Healthcare: Fiscal Q2 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/prestige-consumer-healthcare-fiscal-q2-earnings-snapshot/616-97982add-3306-4774-999b-a2b1636918b5?ref=bullished.co) — Associated Press
- [Prestige Consumer Healthcare Inc. Reports Fiscal 2027](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co) — globenewswire.com